In this study, we investigated the efficacy of ICI plus chemotherapy for advanced NSCLC patients with EGFR-TKI resistance in a real-word setting and explored potential peripheral blood immune cells-related biomarkers through full spectrum flow cytometry. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.